IQVIA„¢ (NYSE:IQV) today launched two new capabilities to support clinical teams more easily and quickly share cross-trial training materials and safety notifications. These features were co-designed, tested, and are now in use by two of the top-five pharmaceutical companies.
IQVIA Technologies cross-trial functionality helps simplify the work of study teams by allowing sponsors and contract research organizations to push training materials and safety notifications to sites across multiple studies, geographic locations, and site roles in just a few clicks. Both systems are administered through a streamlined dashboard that allows users to easily push and track trainings and safety notifications. These upgrades reduce site workload by ensuring the required clinical trainings and safety notifications are distributed and tracked across all trials, removing redundancies in training or safety acknowledgement. These capability enhancements are now available for use on all IQVIA full-service clinical studies.
Our latest platform upgrades help ensure that sponsors, IQVIA, and other CROs can notify sites about safety events and trainings from one centralized dashboard, while removing duplicative activities that were previously inherent in the process. Simply put, this makes it easier for everyone, said Tal Rosenberg, senior vice president, Global Technology Solutions at IQVIA.
Features and benefits include:
- Simple dissemination, receipt, acknowledgement, and tracking of safety notifications and training.
- Reduced workload for sites and study teams.
- Transparency in audit-trail documentation through automatic tracking of notification, acknowledgement.
- Cost and time savings.
- Decreased audit and legal liability.
- Automatic identification of noncompliant site personnel for training and safety acknowledgement.
IQVIA Technologies commitment is to support better decision-making through new technologies that extract deep insights using robust clinical data, advanced analytics, and healthcare expertise.
Additional information about the site portal is available at https://www.drugdev.com/iqvia-lms/ and https://www.drugdev.com/iqvia-safety-notifications/.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE„¢, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 58,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIAs insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Tor Constantino, IQVIA Media Relations ([email protected])
Andrew Markwick, IQVIA Investor Relations ([email protected])